Vycor Medical (Vycor Medical) Cash And Cash Equivalents : $0.04 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Vycor Medical Cash And Cash Equivalents?

Vycor Medical's quarterly cash and cash equivalents declined from Sep. 2023 ($0.07 Mil) to Dec. 2023 ($0.06 Mil) but then stayed the same from Dec. 2023 ($0.06 Mil) to Mar. 2024 ($0.04 Mil).

Vycor Medical's annual cash and cash equivalents declined from Dec. 2021 ($0.09 Mil) to Dec. 2022 ($0.04 Mil) but then increased from Dec. 2022 ($0.04 Mil) to Dec. 2023 ($0.06 Mil).

Vycor Medical Cash And Cash Equivalents Historical Data

The historical data trend for Vycor Medical's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vycor Medical Cash And Cash Equivalents Chart

Vycor Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.06

0.05

0.09

0.04

0.06

Vycor Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.05	0.05	0.07	0.06	0.04

Vycor Medical Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Vycor Medical (OTCPK:VYCO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Vycor Medical Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Vycor Medical's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Vycor Medical (Vycor Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vycor Medical Inc (OTCPK:VYCO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487

Website

https://www.vycormedical.com

Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.

Executives

David Cantor	director, officer: President	1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000
Adrian Liddell	director, officer: Chairman	ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP
Peter C Zachariou	director, 10 percent owner, officer: Chief Executive Officer	C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014
Lowell Rush	director	C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394
Oscar Bronsther	director	4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Steven Girgenti	director	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Fountainhead Capital Management Ltd	10 percent owner	PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP

Vycor Medical (Vycor Medical) Headlines

From GuruFocus

Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement

By Marketwired Marketwired • 06-30-2020

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2017

By ACCESSWIRE AccessWire • 04-12-2019

Vycor Value Could be Unlocked with These Major Partnerships

By Last Financier Last Financier • 12-05-2014

Vycor Medical Reports Financial Results for the year ended December 31st, 2019

By Marketwired Marketwired • 03-27-2020

New Study Shows Vision Rehab Treatment Effective for Stroke and Injury Related Blindness

By Marketwired Marketwired • 02-27-2020

Treatment for blindness successful in largest ever study

By Marketwired Marketwired • 02-26-2020

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2018

By ACCESSWIRE AccessWire • 04-12-2019